Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2022.6051
Abstract: Importance Lipid pathways have been implicated in the pathogenesis of psoriasis, and some lipid-lowering drugs, such as statins, are hypothesized to have disease-modifying properties. However, large population-level studies are scarce, and causal interpretation of results… read more here.
Keywords: lowering drugs; risk psoriasis; lipid lowering; risk ... See more keywords
Participation of Women and Older Participants in Randomized Clinical Trials of Lipid-Lowering Therapies
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.5202
Abstract: Key Points Question Are women and older participants adequately represented in randomized clinical trials of lipid-lowering therapy? Findings In this systematic review of 60 trials with 485 409 participants that were conducted between 1990 and 2018,… read more here.
Keywords: trials lipid; older participants; women older; randomized clinical ... See more keywords
Temporal Changes in Obesity-Related Medication After Bariatric Surgery vs No Surgery for Obesity.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA surgery"
DOI: 10.1001/jamasurg.2023.0252
Abstract: Importance Bariatric surgery can resolve hyperlipidemia, cardiovascular disease, and diabetes, but the long-term postoperative trajectories of medications for these conditions are unknown. Objective To clarify the long-term use of lipid-lowering, cardiovascular, and antidiabetic medication after… read more here.
Keywords: medication; surgery; obesity; lipid lowering ... See more keywords
Influence of intensive lipid‐lowering on CT derived fractional flow reserve in patients with stable chest pain: Rationale and design of the FLOWPROMOTE study
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cardiology"
DOI: 10.1002/clc.23895
Abstract: Coronary CT angiography (CTA) derived fractional flow reserve (FFRCT) shows high diagnostic performance when compared to invasively measured FFR. Presence and extent of low attenuation plaque density have been shown to be associated with abnormal… read more here.
Keywords: derived fractional; physiology; lipid lowering; fractional flow ... See more keywords
2-Hydroxy-4-methoxy benzoic acid attenuates the carbon tetra chloride-induced hepatotoxicity and its lipid abnormalities in rats via anti-inflammatory and antioxidant mechanism
Sign Up to like & getrecommendations! Published in 2017 at "Inflammation Research"
DOI: 10.1007/s00011-017-1054-2
Abstract: Background and aimLiver inflammation stimulates various inflammatory cytokines and initiates injury through oxidative stress. The aim of this study was to curtaile the liver injury through natural principles such as 2-hydroxy-4-methoxy benzoic acid (HMBA).MethodsThe current… read more here.
Keywords: tetra chloride; methoxy benzoic; carbon tetra; benzoic acid ... See more keywords
Do acute coronary events affect lipid management and cholesterol goal attainment in Germany?
Sign Up to like & getrecommendations! Published in 2018 at "Wiener Klinische Wochenschrift"
DOI: 10.1007/s00508-018-1375-3
Abstract: SummaryObjectiveTo document utilization of lipid-lowering therapy, attainment of low-density lipoprotein cholesterol target values, and cardiovascular outcomes in patients hospitalized for acute coronary syndrome in Germany.MethodsThe Dyslipidemia International Study II was a multicenter, observational study of the prevalence… read more here.
Keywords: lowering therapy; density lipoprotein; cholesterol; acute coronary ... See more keywords
Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved?
Sign Up to like & getrecommendations! Published in 2021 at "Wiener klinische Wochenschrift"
DOI: 10.1007/s00508-021-01978-w
Abstract: Cardiovascular disease (CVD) is the most frequent cause of death in Austria. The European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines recommend intensive lipid lowering therapy (LLT) in patients at high or very high… read more here.
Keywords: lipid lowering; therapy; primary secondary; intensity ... See more keywords
Lipid-Lowering Biotechnological Drugs: from Monoclonal Antibodies to Antisense Therapies—a Clinical Perspective
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-07082-x
Abstract: While low density lipoprotein cholesterol (LDL-C) remains a key contributor of atherosclerotic cardiovascular disease (ASCVD), additional risk factors identified through epidemiological and genetic studies have ushered in a fertile era of drug discovery in lipid-lowering… read more here.
Keywords: risk; biotechnological drugs; risk factors; clinical trials ... See more keywords
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-021-00497-3
Abstract: Increased levels of low-density lipoprotein cholesterol (LDL-C) are recognized as a primary risk factor for atherosclerotic cardiovascular disease, which remains the leading cause of death worldwide. Lowering LDL-C levels clearly reduces the risk of cardiovascular… read more here.
Keywords: drug therapy; approach implementation; therapy critical; lowering drug ... See more keywords
Contemporary Management of Dyslipidemia
Sign Up to like & getrecommendations! Published in 2022 at "Drugs"
DOI: 10.1007/s40265-022-01691-6
Abstract: The treatment of dyslipidemia continues to be a dynamic and controversial topic. Even the most appropriate therapeutic range for lipid levels—including that of triglycerides and low-density lipoprotein cholesterol—remain actively debated. Furthermore, with ever-increasing options and… read more here.
Keywords: review; dyslipidemia; lipid lowering; management dyslipidemia ... See more keywords
Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real‐world cohort of persons with human immunodeficiency virus and uninfected persons
Sign Up to like & getrecommendations! Published in 2019 at "American Heart Journal"
DOI: 10.1016/j.ahj.2018.11.012
Abstract: Background Risks for cardiovascular diseases, including myocardial infarction and stroke, are elevated in people with HIV infection (PWH). However, no trials of statin utilization with clinical cardiovascular disease (CVD) end points have been completed in… read more here.
Keywords: pwh; uninfected persons; statin utilization; cohort ... See more keywords